• 1. Palonosetron attenuates 1,2-dimethyl hydrazine induced preneoplastic colon damage through downregulating acetylcholinesterase expression and up-regulating synaptic acetylcholine concentration
  Rakesh K. Mishra,Shreesh Raj Sammi,Jitendra K. Rawat,Subhadeep Roy,Manjari Singh,Swetlana Gautam,Rajnish K. Yadav,Uma Devi,Mohd Nazam Ansari,Abdulaziz S. Saeedan,Shubhini A. Saraf,Rakesh Pandey,Gaurav Kaithwas RSC Adv. 2016 6 40527
• 2. Rh(iii)-Catalyzed intramolecular redox-neutral cyclization of alkenes via C–H activation
  Zhuangzhi Shi,Mélissa Boultadakis-Arapinis,Dennis C. Koester,Frank Glorius Chem. Commun. 2014 50 2650
• 3. Sterically controlled isodesmic late-stage C–H iodination of arenes
  Mirxan Farizyan,Rita de Jesus,Jyotirmoy Dey,Manuel van Gemmeren Chem. Sci. 2023 14 4357
• 4. He-Wei granules inhibit chemotherapy-induced vomiting (CINV) in rats by reducing oxidative stress and regulating 5-HT, substance P, ghrelin and obestatin
  Zehai Song,Hang Chang,Na Han,Zhihui Liu,Zhonglin Wang,Hao Gao,Jun Yin RSC Adv. 2017 7 43866
• 5. Synthesis and evaluation of novel quinuclidinone derivatives as potential anti-proliferative agents
  Jigar Y. Soni,Shridhar Sanghvi,R. V. Devkar,Sonal Thakore RSC Adv. 2015 5 82112

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives Isoquinolones and derivatives

Palonosetron: A Comprehensive Overview

Palonosetron (CAS No. 135729-61-2) is a highly effective antiemetic agent that has revolutionized the management of chemotherapy-induced nausea and vomiting (CINV). As a second-generation 5-HT₃ receptor antagonist, Palonosetron has demonstrated superior efficacy and safety compared to earlier agents in its class. This article provides an in-depth exploration of Palonosetron, including its chemical structure, pharmacology, clinical applications, and recent advancements in research.

The chemical structure of Palonosetron is characterized by a unique bicyclic framework that enhances its selectivity for the 5-HT₃ receptor. This structural innovation contributes to its potent antiemetic effects and reduced risk of side effects. Recent studies have highlighted the importance of Palonosetron's pharmacokinetic profile, which ensures sustained plasma levels and prolonged efficacy. Researchers have also investigated the compound's ability to cross the blood-brain barrier, further elucidating its mechanism of action.

In terms of pharmacology, Palonosetron works by selectively blocking the 5-HT₃ receptors located in the chemoreceptor trigger zone (CTZ) and the gastrointestinal tract. This mechanism effectively prevents the transmission of nausea signals to the brain, thereby alleviating chemotherapy-induced nausea and vomiting. A 2023 study published in *Oncology Research* revealed that Palonosetron exhibits a higher receptor occupancy rate compared to other 5-HT₃ antagonists, which correlates with its superior clinical outcomes.

Clinically, Palonosetron has become a cornerstone in the prophylaxis of CINV, particularly for patients undergoing highly emetogenic chemotherapy regimens. Its efficacy has been validated in numerous randomized controlled trials, including a landmark study comparing Palonosetron with ondansetron and granisetron. The results demonstrated that Palonosetron significantly reduces both acute and delayed nausea and vomiting. Furthermore, recent research has explored the use of Palonosetron in combination with other antiemetic agents, such as dexamethasone, to enhance therapeutic outcomes.

One of the most promising areas of research surrounding Palonosetron involves its potential application beyond chemotherapy-induced nausea and vomiting. Emerging studies suggest that Palonosetron may also be effective in managing postoperative nausea and vomiting (PONV), a common complication following surgical procedures. A 2023 meta-analysis published in *Anesthesia & Analgesia* found that Palonosetron significantly reduces the incidence of PONV compared to traditional antiemetics like ondansetron.

In addition to its clinical applications, recent advancements in drug delivery systems have expanded the utility of Palonosetron. For instance, researchers have developed extended-release formulations that provide prolonged antiemetic effects with fewer administrations. These innovations are expected to improve patient compliance and reduce healthcare costs associated with CINV management.

The safety profile of Palonosetron remains favorable, with minimal side effects reported in clinical trials. Common adverse events include headache and constipation, which are generally mild and transient. Importantly, Palonossetron does not exhibit significant drug-drug interactions, making it a suitable option for patients on multiple medications.

In conclusion, Palonossetron (CAS No. 135729-61-2) stands as a testament to advancements in antiemetic therapy. Its unique chemical structure, robust pharmacology, and broad clinical applications have established it as a leader in the management of chemotherapy-induced nausea and vomiting. As research continues to uncover new indications and delivery methods for Palonossetron, its role in oncology care is likely to expand further.

• 135729-78-1((S)-N-(1-Azabicyclo2.2.2oct-3-yl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamide)
• 135729-56-5(Palonosetron)
• 149653-99-6((5R)-3-(3R)-1-azabicyclo2.2.2octan-3-yl-3-azatricyclo7.3.1.0,5,13trideca-1(13),9,11-trien-2-one)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)